Mass. provider opens innovation center

Atrius Health is the latest health system to open an innovation center.

The organization, headquartered in Newton, Mass., is the northeast’s leading nonprofit independent multi-specialty medical group and home care agency and hospice, will devote its new center to developing and improving patient-centered care delivery models. Atrius Health plans to invest $10 million towards this objective, according to a release.

"As the industry continues to move towards increased risk sharing, accountability and transparency around performance, increased patient engagement, and demands for big gains in efficiency, it is requiring us to rethink how we deliver care," said Daniel Burnes, MD, transition CEO of Atrius Health.

The Innovation Center will focus on programs developed within the Atrius Health medical practices as well as on external programs that have a strong likelihood for improving quality and experience for a significant number of patients and demonstrating some financial return. Atrius Health practices and the Innovation Center will work together to generate and assess ideas, taking necessary steps for implementation once an idea is proven. Each selected project will undergo a rigorous and structured vetting process that includes generating ideas, thorough research, and testing before its launch.

The Innovation Center will be an independent business unit within Atrius Health. 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.